Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

51.08 +0.05 (+0.10%)
Streaming Delayed Price Updated: 12:39 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3
For the third straight year, serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) will host an annual conference that combines elements of business, pop culture 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Why Novavax Stock More Than Doubled Today
A cloud of doubt hanging over the company just gave way to some sunshine. 
Via The Motley Fool
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely? 
Via The Motley Fool
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress. 
Via InvestorPlace
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements. 
Via Benzinga
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous... 
Via Benzinga
3 Biotech Stocks to Buy Now: May 2024
As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are. 
Via InvestorPlace
3 Things You Need to Know If You Buy Novavax Today
The vaccine maker's recovery story is looking brighter. 
Via The Motley Fool
ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Roaring Kitty’s Rally Cry: 3 Meme Stocks to Pounce On Now
Jump into action with NVAX, HOOD and WKHS as top meme stocks to buy, offering the chance to capitalize on short squeezes and momentum. 
Via InvestorPlace
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
The biotech still hasn't lost momentum. 
Via The Motley Fool
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths... 
Via The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas. 
Via Benzinga
Is DoubleVerify’s 39% Haircut a Buying Opportunity?
Digital advertising verification and measurement solutions provider DoubleVerify Holdings Inc. (NYSE: DV) shares took a 39% plunge on its Q1 2024 earnings 
Via MarketBeat
Topics Artificial Intelligence Fraud Malware
Exposures Artificial Intelligence Information Security Legal
3 Stocks Under $2 That Can Trade in Double Digits by 2025
These stocks under $2 are likely to surge higher as they represent companies with impending growth catalysts. 
Via InvestorPlace
Novavax Stock Just Tripled. Is It Too Late to Buy?
Novavax shares have soared and plummeted in recent years. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Cheap Biotech Stocks to Buy Now: May 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
Exposures Product Safety
3 Meme Stocks That Are Likely to Crater in 2024
These are the meme stocks to avoid as they represent fundamentally weak companies with a sluggish growth outlook. 
Via InvestorPlace
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
NVAX Stock Alert: Novavax Just Hit a New 52-Week High
Novavax stock is heading higher on Friday as NVAX investors celebrate it reaching a new 52-week high following a deal with Sanofi. 
Via InvestorPlace
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.